Answers are grounded in this paper and cite their sources.
Review demonstrates improved brain and retinal maturation with docosahexaenoic acid intake during pregnancy and infancy, highlighting the need for standardized dosing.
Docosahexaenoic acid (DHA) dietary supplementation has highly increased in recent years. Sufficient DHA supplementation during gestation and early childhood is supremely clinical important. Some substantiation has been constructed for neurocognitive and brain benefits of supplementation with long chain polyunsaturated fatty acids (LC PUFA) such as DHA by the time before, during and after gestation. Acceptable in quality and quantity of DHA availability in the fetus and infant optimizes brain and retinal maturation development by affecting neurotransmitter pathways. DHA role as anti-inflammatory agent is significantly interceded over modulating of signaling pathways by directly binding to receptors or alteration in lipid raft formation and receptor presentation. Here, we intend to review the current progress on DHA supplementation, specifically brain development of fetus during pregnancy and infant, as a pharmacologic agent with both preventative and therapeutic endeavors. These findings provide benefits of routine DHA supplementation in pre-, during and post-gestation to improve neurodevelopmental outcomes in fetus, infant and early childhood. However, optimal composition of the supplement and dosing and treatment strategies still need to be determined toward advance nutrient for routine DHA dietary supply.
No takes yet. Share an insight, caveat, or question.
Satriyanto et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: